NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 356 filers reported holding NEKTAR THERAPEUTICS in Q1 2019. The put-call ratio across all filers is 1.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,264 | -84.3% | 57,528 | -84.8% | 0.00% | -100.0% |
| Q2 2023 | $217,655 | +77.0% | 378,398 | +595.3% | 0.00% | 0.0% |
| Q4 2022 | $122,989 | -27.2% | 54,420 | +22.4% | 0.00% | 0.0% |
| Q2 2022 | $169,000 | -72.2% | 44,471 | +57.9% | 0.00% | -94.7% |
| Q4 2019 | $608,000 | +85.4% | 28,157 | +205.9% | 0.02% | -75.6% |
| Q2 2019 | $328,000 | +60.0% | 9,205 | +47.6% | 0.08% | -11.4% |
| Q4 2018 | $205,000 | -50.0% | 6,237 | -7.3% | 0.09% | +60.0% |
| Q3 2018 | $410,000 | – | 6,726 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |